 | Stay connected to Formulary
Receive web-exclusive articles, clinical news, and conference updates!
|
 Formulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians. Register now (it's free and quick) or Find out more.
Keep visiting FormularyJournal.com for fresh content, news, opinions, editor's blogs and more.  |
 | |  | |
With the recent termination of the ALTITUDE trial due to increased risk of serious adverse events (non-fatal stroke, renal complications, hyperkalemia, and hypotension) in high-risk patients receiving aliskiren in combination with an ACE inhibitor or ARB medication, which of the following best describes the actions you deem most appropriate for managing the use of aliskiren-containing medications? | | | Immediately remove all aliskiren-based products from formulary and recommend switching patients to alternative anti-hypertensive medications | | 23% | | | Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of ALL patients on an aliskiren product | | 21% | | |
| Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of only high-risk patients on such an aliskiren combo | | 21% | | | Implement new prior authorization and/or new contingent therapy edits on aliskiren products to minimize new patient starts on such combinations | | 14% | | | Do nothing for the time-being until more definitive direction is provided from FDA | | 21% | |
| |  | | | |
| |
|